Skip to content

Study for the clinical effect evaluation of strengthening spleen and lowering the stomach Qi therapy for reflux esophagitis with spleen deficiency

Study for the clinical effect evaluation of strengthening spleen and lowering the stomach Qi therapy for reflux esophagitis with spleen deficiency

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025036
Enrollment
Unknown
Registered
2019-08-08
Start date
2018-01-19
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

reflux esophagitis

Interventions

Sponsors

Dong Fang Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Clinical diagnosis of Western medicine in accordance with reflux esophagitis, endoscopic in accordance with the diagnosis of reflux esophagitis; 2) in line with reflux esophagitis TCM deficiency gas inverse syndrome (spleen deficiency type) diagnosis; 3) Male and female aged 18-65 years old, voluntarily signed the subject's informed consent.

Exclusion criteria

Exclusion criteria: 1. Anti-acid and heartburn caused by severe organic lesions and other diseases or drugs; 2. Persons with disabilities under the law (blindness, deafness, mute, intellectual impairment, physical disability); 3. Pregnant or prepared for pregnancy, lactating women; 4. Allergic physique or allergic to research drug ingredients; 5. Suspected or indeed has a history of alcohol and substance abuse; 6. Patients who have participated in other clinical studies within 3 months; 7. Patients who have used the relevant therapeutic drugs within 1 months; 8. Unclear description of self-symptoms or investigation of non-authors; 9. with cardiac achalasia, esophageal fissure hernia, high intestinal obstruction and gastrointestinal surgery history; 10. with tumor, digestive system ulcer and other sexual diseases; 11. with hepatobiliary and pancreatic diseases, pregnancy, connective tissue disease and serious systemic diseases; 12. with circulatory system, nervous system, urinary tract and other serious primary diseases and mental patients; 13. take drugs that can cause anti-acid or heartburn symptoms.

Design outcomes

Primary

MeasureTime frame
motilin;VIP;Ghrelin;

Countries

China

Contacts

Public ContactLiping ZHANG

Beijing University of Chinese Medicine;Dongfang Hospital of Beijing University of Chinese Medicine

lpzhang2005@126.com+86 13911216028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026